Abrégé

The present invention relates to a method for determining the measure of the degree of an obstructive sleep apnea and/or its consequence by means of the following steps: defining a measure of the degree of an obstructive sleep apnea and/or its consequence, providing two EEG measurement signals of an electroencephalography at the electroencephalography points of an 10-20 international EEG system, dividing the EEG measurement signals into frequency bands, determining at least one cross-frequency modulation index using data from at least two different frequency bands, determining the measure of the degree of an obstructive sleep apnea and/or its consequences by means of the at least one cross-frequency modulation index. The present invention relates to a method for determining the measure of the degree of an obstructive sleep apnea and/or its consequence by means of the following steps: defining a measure of the degree of an obstructive sleep apnea and/or its consequence, providing two EEG measurement signals of an electroencephalography at the electroencephalography points of an 10-20 international EEG system, dividing the EEG measurement signals into frequency bands, determining at least one cross-frequency modulation index using data from at least two different frequency bands, determining the measure of the degree of an obstructive sleep apnea and/or its consequences by means of the at least one cross-frequency modulation index. The invention further relates to a device for carrying out the method.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/256 - Électrodes portables, p. ex. avec des sangles ou des bandes
• A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

The present invention relates to a mannose-HSA based nanocarrier system, and a pharmaceutical composition containing the same for delivery of immunomodulatory drugs. The present invention further relates to a method of manufacturing said mannose-HSA nanocarrier system.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 35/00 - Agents anticancéreux
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit

Abrégé

The invention is based on the detection of the involvement of the K63-specific deubiquitinase CYLD in the manifestation of autism spectrum disorder in a mouse model. The invention therefore provides methods for the diagnosis of such a disorder as well as methods for the development of new autism diagnostics. Further provided are means and methods for use in therapeutically modulating any manifestation of an autism spectrum disorder, or intellectual disability (ID), in a mammal or associated neuropsychiatric manifestations.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Roller shutter rod, comprising a body with a head end and a foot end, wherein a hook is arranged at one of the two ends and a chamber for receiving the hook is formed at the other of the two ends a chamber is formed for receiving the hook, wherein the chamber is formed in two parts in such a way that it enables a hook to be received in two directions opposite to a centre plane of the roller shutter rod.

Classes IPC  ?

• E06B 9/15 - Volets à rouleau avec des éléments de fermeture constitués par des lattes ou analogues

Abrégé

Many next-generation biomaterials will need the ability to not only promote healthy tissue integration but to simultaneously resist bacterial colonization and resulting biomaterials-associated infection. For this purpose, antimicrobial nanofibers of polycaprolactone (PCL) were fabricated by incorporating calcium peroxide. PCL nanofibers containing different ratios of calcium peroxide (1%, 5% and 10% (w/w)) with or without ascorbic acid were fabricated using an electrospinning technique. Antimicrobial evaluations confirmed the inhibitory properties of the nanofibers on the growth of E. coli and S. epidemidis because of a significant burst release of calcium peroxide from the nanofibers. Analysis of tissue cell response showed that despite an initial toxic effect over the first 24 h, after 4 days of culture, osteoblast viability and morphology were both healthy. These results demonstrate that oxygen-generating nanofibers can be designed and developed to provide a short-term peroxide-based antimicrobial response while still maintaining attractive tissue-integration properties.

Classes IPC  ?

• A61K 33/40 - Peroxydes
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to methods for detecting the presence and/or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4), ADAMTS9, ADAPT, ADAPTI, ADAPT-2, FIB-4 or Pro-C3 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and/or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to novel tumor-associated antigens, which elicit a T-cell response independently from a presentation by MHC. PD-L1 was found to be a target of CD8-positive T-cell clones which could detect their target antigen on the surface of HLA I-negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Also provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells specifically reactive to the antigens of the invention in an MHC-independent manner.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61K 31/365 - Lactones
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a device (10) for retracting and extending a flexible and/or foldable material sheet (20), which comprises a holding element such as a winding shaft (12) and a drive (14). The material sheet (20) is able to be retracted and extended on the holding element, in particular wound and unwound around the holding element (12) or gathered and ungathered on the holding element. The drive (14) is designed to drive a translational movement of the device along a travel path. The device (10) is designed, as a result of the translational movement driven by the drive (14), to vary an extended portion of the material sheet (20) by retracting or extending the material sheet (20). The invention also relates to a system (100) for selectively covering a surface (210) with such a device (10) and to a building structure (200) which is equipped with such a system (100).

Classes IPC  ?

• E06B 9/66 - Dispositions ou dispositifs de manœuvre, de guidage ou de verrouillage pour fermetures à rouleauTambours à ressortsTambours à rubanLeurs dispositions de contrepoids avec un rouleau situé dans le bas
• E04H 4/10 - Dispositifs de couverture constitués d'un matériau flexible

Abrégé

Disclosed herein is a method of and an apparatus for combined ion mobility and mass spectrometry analysis, the method comprising the following steps: introducing precursor ions (34) into a trap configured for trapping ions and for selectively ejecting trapped ions according to their m/z ratio, selectively ejecting precursor ions (34) having m/z values falling within at least one controllable ejection window from said trap (15), sequentially releasing precursor ions (34) from said IMS (16) according to their ion mobility, introducing said released precursor ions (34) into a mass filter (26) having a controllable mass window, fragmenting the precursor ions (34) transmitted through said mass filter (26) to generate fragment ions, and carrying out a mass spectrometry measurement on said fragment ions, wherein each fragment ion is associated with a mass window and an ion mobility (IM) range.

Classes IPC  ?

• G01N 27/623 - Spectrométrie de mobilité ionique combinée à la spectrométrie de masse
• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules

Abrégé

The invention relates to a movable solar cell device (10) having a flexible and/or foldable carrier substrate (12) and an arrangement of solar cells (14) disposed on the carrier substrate (12). The solar cell device (10) is movable by being rolled up or gathered up. The invention also relates to a building structure (110, 120) which has a light-permeable surface (130, 140) and a movable solar cell device (10) of this kind, which is disposed in front of or behind the light-permeable surface (130, 140). The invention also relates to a method for operating a movable solar cell device (10) of this kind.

Classes IPC  ?

• H02S 20/30 - Structures de support mobiles ou réglables, p. ex. pour réglage de l’angle
• H02S 30/20 - Modules PV escamotables ou pliables
• H02S 20/22 - Structures de support directement fixées sur un objet inamovible spécialement adaptées pour les bâtiments

Abrégé

The present invention relates to hydrophilic (co)polymers having chemically reactively (covalently) bound anchor groups and/or crosslinker molecules that permit attachment to the parent substrate or linkage of these polymers to networks. The invention further relates to hydrogels and coatings, especially implant coatings, comprising the polymers of the invention, and to medical devices, such as implants, that have been coated with a coating of the invention.

Classes IPC  ?

• C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
• C08F 8/12 - Hydrolyse
• C09D 133/24 - Homopolymères ou copolymères d'amides ou d'imides

Abrégé

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/4995 - Pyrazines ou pipérazines formant une partie de systèmes cycliques pontés
• A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or prevention of organ or tissue fibrosis. The inhibitor of the present invention is characterized in that it interferes with Fra-1 or Fra-2 expression, resulting in a reduction in the amount of Fra-1 or Fra-2 in said fibrogenic cells to levels found in non-fibrotic healthy cells or tissues.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique

Abrégé

Novel inhibitors of the Tissue Factor-Protease Activated Receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF). In-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (MI), comprise the steps of (i) determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-β1 in a biological sample collected from said subject, and (ii) comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-β1 are indicative for an increased risk of developing IHF or adverse remodeling following MI.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for detecting and/or predicting the severity and/or chronicity of a systemic pulmonary disease (SPD) in a patient, comprising determining the expression of at least two markers selected from the group consisting of macrophage marker CD163, matricellular fibrosis marker thrombospondin-2 (Tsp2), and (cardiovascular) inflammation/repair marker growth differentiation factor 15 (GDF-15) in a sample obtained from said patient, optionally with complementation by insulin like growth factor binding protein 7 (IGFBP7). The method is particularly useful in case of SPDs such as influenza infection, such as, for example, influenza A virus infection, interstitial lung disease (ILD, IPF), acute respiratory distress syndrome (ARDS), and coronavirus infection, such as, for example, COVID19 and long COVID19.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Rheum palmatumRheum palmatum) root extract and one or more additives selected from the group consisting of Acemannan and/or Glucomannan, or plant extracts containing said compounds for use in the prevention or treatment of oral or dental disorders or dysfunctions. Furthermore, the invention relates to a mouth rinse solution or dentifrice composition for use in oral or dental care.

Classes IPC  ?

• A61K 36/708 - Rheum (rhubarbe)
• A61K 36/886 - Aloeaceae (famille de l'aloès), p. ex. aloe vera
• A61K 36/258 - Panax (ginseng)
• A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p. ex. dentifricesBains de bouche
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites

Abrégé

A method for classifying a polysomnography recording into defined sleep stages. The method comprises essentially the following steps: classifying the sleep of a human being into a grid with different sleep stages, collecting a plurality of information on bodily functions over a predetermined period of time in the form of data, wherein collecting the plurality of information comprises at least one measuring and recording of brain electrical activity data over a predetermined period of time during sleep of a person, subdividing the collected data into time-dependent data blocks, selecting a predetermined number of data blocks from the data blocks, wherein said data blocks include data on the electrical activity of the brain, automatically evaluating the brain electrical activity data in each selected data block using a cross-frequency coupling method, and automatically assigning the evaluated data blocks to a sleep stage.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma

Abrégé

The present invention relates to a method for determining a scale for the degree of obstructive sleep apnoea and/or the after-effect thereof using the following steps: - defining a scale for the degree of obstructive sleep apnoea and/or the after-effect thereof, - providing two EEG measurement signals from an electroencephalograph at the electroencephalograph points of an international 10-20 EEG system, - dividing the EEG measurement signals into frequency bands, - determining at least one cross frequency modulation index using data from at least two different frequency bands, - determining the scale for the degree of obstructive sleep apnoea and/or the after-effect thereof using the at least one cross frequency modulation index. The invention further relates to a device for performing the method.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma

Abrégé

Autologous prevascularized breast tissue constructs created via 3D printing and methods for 3D printing autologous prevascularized breast tissue constructs. The method comprises steps of: (i) providing a triculture consisting of adipose mesenchymal stem cells, fibroblasts, and endothelial progenitor cells, (ii) mixing the triculture cells with a bioink composed of biopolymers, (iii) printing three-dimensional structures of the breast tissue construct using the triculture-added bioink from step (ii), where the cells of the triculture are pretreated with growth media before printing so that the endothelial progenitor cells differentiate into endothelial cells and the adipose mesenchymal stem cells differentiate into adipocytes. After 3D printing, the development of vascular-like structures is induced.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• B33Y 10/00 - Procédés de fabrication additive
• B33Y 80/00 - Produits obtenus par fabrication additive
• B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive

Abrégé

2222) for use in the prevention or treatment of wounds, and/or pathological conditions requiring wound healing, tissue regeneration and/or bone regeneration. The present invention is in particular suitable for the prevention or treatment of a gum disease.

Classes IPC  ?

• A61K 31/728 - Acide hyaluronique
• A61K 33/08 - OxydesHydroxydes
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p. ex. dentifricesBains de bouche
• A61Q 11/02 - Préparations pour désodoriser, décolorer ou désinfecter les prothèses dentaires

Abrégé

The present invention relates to method of detecting endocannabinoids from dried blood spots. The present invention further relates to a method for diagnosing and/or monitoring a disease or condition which is related to a change of the concentration of endocannabinoid(s) in the blood or plasma, which comprises the detection method. The present invention further relates to a method for control testing.

Classes IPC  ?

• G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques

Abrégé

The invention relates to a roller blind slat (1, 1a, 1b, 1c) comprising a body (8) having a head end (12) and a foot end (14), wherein a hook (2) is arranged at one of the two ends (12, 14) and a chamber (3) for receiving the hook (2) is formed at the other of the two ends (12, 14), wherein the chamber (3) is formed in two parts in such a way as to enable a hook (2) to be received in two opposite directions with respect to a central plane (22) of the roller blind slat (1, 1a, 1b, 1c).

Classes IPC  ?

• E06B 9/15 - Volets à rouleau avec des éléments de fermeture constitués par des lattes ou analogues
• E06B 9/58 - Dispositifs de guidage

Abrégé

According to the disclosure, a method for reconstructing a brain network (205), comprises providing, in a memory of a computing device, an image of at least a section of a subject's brain (201); determining, in a processing unit of the computing device, a three-dimensional volume model (202) of the section of the subject's brain (201); segmenting, by the processing unit, the volume model (202) into a plurality of sub-volumes, each sub-volume corresponding to an anatomical subfield of the subject's brain (201) and having a volume value; for each of the sub-volumes, determining, by the processing unit, a modified volume for the sub-volume, wherein determining said modified volume comprises calculating said modified volume based on the volume value of the sub-volume and variables multiplied with constants, wherein the constants are constants determined for a population, comprising a plurality of individuals, to which the subject belongs; for each combination of two sub-volumes, determining, by the processing unit, a similarity between the sub-volumes, based on a comparison of the respective modified volume for each of the sub-volumes; and determining, by the processing unit, a brain network (205) for the section of the subject's brain (201). The brain network (205) comprises nodes (206), each node (206) representing one of the sub-volumes, and edges (207), each edge (207) connecting two nodes (206) and being indicative of the determined similarity between the sub-volumes. At least one of the steps from the group of storing the brain network (205) in the memory of the computing device, displaying the brain network (205) on a display unit of the computing device, and sending the brain network (205) to a remote computing device via a transmission unit of the computing device is performed. Further, a method for monitoring a brain network, a computing device, a computer program product and a computer-readable storage medium are provided.

Classes IPC  ?

• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique

Abrégé

The invention is based on the detection of the involvement of the K63-specific deubiquitinase CYLD in the manifestation of autism spectrum disorder in a mouse model. The invention therefore provides methods for the diagnosis of such a disorder as well as methods for the development of new autism diagnostics. Further provided are means and methods for use in therapeutically modulating any manifestation of an autism spectrum disorder, or intellectual disability (ID), in a mammal or associated neuropsychiatric manifestations.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to methods for detecting whether a subject suffers from an autoimmune disease, such as, for example, antiphospholipid syndrome (APS), by detecting antiphospholipid antibodies (aPL) in a sample using a novel target, the lysobisphosphatidic acid (LBPA) bound to the endothelial protein C receptor (EPCR) or an LBPA-binding fragment thereof. Furthermore, the present invention relates to methods for identifying an inhibitor of endothelial protein C receptor (EPCR) function in autoimmune disease, preferably without a side effect on EPCR regulatory function in coagulation, and a method for producing a pharmaceutical composition comprising the steps of identifying a potential inhibitor, and suitably formulating said potential inhibitor into a pharmaceutical composition. Moreover, the present invention relates to said inhibitor as identified or said pharmaceutical composition for use in the prevention and/or treatment of an autoimmune disease, such as, for example, an antiphospholipid syndrome, in a subject. Furthermore, the present invention relates to a method for treating and/or preventing an autoimmune disease, such as, for example, antiphospholipid syndrome, in a subject.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• C07K 14/81 - Inhibiteurs de protéase
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

Prooxidative chain-transfer agents for use in the treatment of a malignant tumour disease, or infectious disease. The prooxidative chain-transfer agents are selected from lipophilic thiols, lipophilic trithiocarbonates, lipophilic, aromatic dithioesters, and lipophilic, aromatic thiols. The compounds amplify the prooxidative activity at the target site and are therefore highly efficient and specific for their targets.

Classes IPC  ?

• A61K 31/265 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbonique, thiocarboniques, thiocarboxyliques, p. ex. acide thio-acétique, acide xanthogénique, acide trithiocarbonique
• A61P 35/00 - Agents anticancéreux
• A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols

Abrégé

A device and method for determining the severity of sleep apnea using electroencephalography and electromyography. The device includes a headgear having a head part sized to cover the head of a patient, at least at the locations where the measuring points C3 and C4 of the electroencephalography are situated, and a chin part, and wherein the head part has two electrodes for sensing EEG-signals of the electroencephalography at the electroencephalography points C3 and C4, and the chin part has at least one electrode for sensing the EMG-signal of the electromyography in the chin.

Classes IPC  ?

• A61N 1/00 - ÉlectrothérapieCircuits à cet effet
• A61B 5/308 - Circuits d’entrée à cet effet spécialement adaptés à des utilisations particulières pour l’électrocardiographie [ECG]
• A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques

Abrégé

Disclosed herein is a method of and an apparatus for combined ion mobility and mass spectrometry analysis, the method comprising the following steps: introducing precursor ions (34) into a trap configured for trapping ions and for selectively ejecting trapped ions according to their m/z ratio, selectively ejecting precursor ions (34) having m/z values falling within at least one controllable ejection window from said trap (15), sequentially releasing precursor ions (34) from said IMS (16) according to their ion mobility, introducing said released precursor ions (34) into a mass filter (26) having a controllable mass window, fragmenting the precursor ions (34) transmitted through said mass filter (26) to generate fragment ions, and carrying out a mass spectrometry measurement on said fragment ions, wherein each fragment ion is associated with a mass window and an ion mobility (IM) range.

Classes IPC  ?

• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• G01N 27/623 - Spectrométrie de mobilité ionique combinée à la spectrométrie de masse

Abrégé

A finger motion rail, and a therapeutic device with a finger motion rail for carrying out a continuous, passive and/or actively assisted movement of a finger and/or thumb. A multi-joint hinge, arranged laterally alongside a finger and/or thumb, for flexion of a metacarpophalangeal joint. The multi-joint hinge is operatively connected via a first connection lever, at least one second connection lever and at least one connection joint, to a mechanism also arranged laterally alongside the respective finger and/or thumb, for flexion of a proximal interphalangeal joint and/or a distal interphalangeal joint. The finger motion rail and therapeutic device is configured as robust against the effect of compressive, tensile and torsional forces, with respect to a longitudinal axis of the finger motion rail, and it permits precise and interference-free execution of an anatomically natural, automated finger movement, for increased chance of successful therapy and the service life of the device.

Classes IPC  ?

• A61H 1/02 - Appareils d'exercice extenseurs ou de ployage

Abrégé

A length adjustment device for a finger motion rail of a therapeutic device, a finger motion rail having such a length adjustment device, a therapeutic device having such a finger motion rail, and a method for adjusting the length of a finger motion rail on a therapeutic device for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a hand. The length adjustment device and adjustment method having a finger motion rail that is automatically moved along an adjustment rail by a drive on a therapeutic device and allows the finger motion rail to be fixed on the adjustment rail and therefore on the therapeutic device at a desired position in order to then be able to carry out a continuous, passive and/or actively assisted movement of a finger and/or of a thumb of a hand in a stable position.

Classes IPC  ?

• A61H 1/02 - Appareils d'exercice extenseurs ou de ployage

Abrégé

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. Said compounds have been identified through methods of pharmacological screening on a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

Classes IPC  ?

• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61K 31/13 - Amines, p. ex. amantadine
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
• A61K 31/415 - 1,2-Diazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/4462 - Pipéridines non condensées, p. ex. pipérocaïne substituées uniquement en position 3
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
• A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
• A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
• A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 31/52 - Purines, p. ex. adénine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Abrégé

Modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. Embodiments of the invention further relate to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening, methods for the preparation of a modified NK-92 that is specific for a target antigen of a target cell in a subject, and to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/73 - CD4
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

A method for classifying or categorizing a polysomnography recording into defined sleep tags.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• A61B 5/0205 - Évaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p. ex. de l'état cardiaque et respiratoire
• A61B 5/087 - Mesure du débit respiratoire
• A61B 7/00 - Instruments d'auscultation
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/369 - Électroencéphalographie [EEG]
• A61B 5/389 - Électromyographie [EMG]
• A61B 5/318 - Modalités électriques se rapportant au cœur, p. ex. électrocardiographie [ECG]
• A61B 5/024 - Mesure du pouls ou des pulsations cardiaques

Abrégé

in-vitroin-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (Ml), comprising the steps of i. determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-β1 in a biological sample collected from said subject, ii. comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-β1 are indicative for an increased risk of developing IHF or adverse remodeling following Ml.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: - dividing the sleep of a person into a pattern with various sleep stages, - acquiring a multiplicity of items of information relating to bodily functions over a predefined period in the form of data, wherein the acquisition of the multiplicity of items of information comprises at least measuring and storing the electrical activity of the brain over a predefined period while a test person is sleeping, - subdividing the acquired data into time-dependent data blocks, - selecting a predefined number of data blocks from the data blocks, wherein these data blocks contain information relating to the electrical activity of the brain, - automatically evaluating the data relating to the electrical activity of the brain in each selected data block by means of a cross-frequency coupling method, - automatically assigning the evaluated data blocks to a sleep stage.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present invention relates to methods for the 3D printing of autologous, prevascularized breast tissue constructs, said methods comprising the steps of: (i) providing a triculture, consisting of adipose mesenchymal stem cells, fibroblasts and endothelial progenitor cells, (ii) mixing the triculture cells with a bioink consisting of biopolymers, (iii) printing three-dimensional structures of the breast tissue construct using the bioink from step (ii), to which the triculture has been added, wherein the cells of the triculture are pretreated with growth media prior to the printing process so that the endothelial progenitor cells differentiate to form endothelial cells and the adipose mesenchymal stem cells differentiate to form adipocytes. After the 3D printing, the development of vascular-like structures is induced. The invention also relates to autologous, prevascularized breast tissue constructs produced by means of such a 3D printing method.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61L 27/24 - Collagène
• A61L 27/38 - Cellules animales
• B33Y 80/00 - Produits obtenus par fabrication additive

Abrégé

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 9/22 - Ribonucléases
• C12N 5/09 - Cellules tumorales
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 35/00 - Agents anticancéreux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Pharmaceutical compositions and pharmaceutical combination preparations. The pharmaceutical compositions and the pharmaceutical combination preparations comprise at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The pharmaceutical compositions or combination preparations may be used in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations may find use for topical application on the skin of a human or animal body.

Classes IPC  ?

• A61K 39/285 - Virus de la vaccine ou virus de la variole
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p. ex. guanosine, acide guanylique
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/38 - Albumines
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The invention relates to a device for assisting with illumination and displaying anatomical boundaries during medical procedures, in particular in the context of an endoscopy, laparoscopy and/or diaphanoscopy, comprising a hollow tube (1) having a proximal end (21) and a distal end (22) and a separate light cable (3), which is guided in a lumen (2) of the hollow tube (1) and is fitted, in its longitudinal extension, with one or more light sources (4) connected in series, the wavelength, frequency and/or intensity of which light sources can be controlled, individually or together, by a control unit (6), wherein the hollow tube (1) can be flexibly shaped and is designed to be light-permeable at least in the region of the light sources (4).

Classes IPC  ?

• A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
• A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
• A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
• A61B 1/005 - Endoscopes flexibles

Abrégé

The present invention relates to nucleic acid molecules encoding a recombinant human cytomegalovirus (HCMV) strain, dense bodies produced by said HCMV strain and preparations of said dense bodies for use in medicine, particularly as a vaccine against HCMV.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to methods for detecting whether a subject suffers from an autoimmune disease, such as, for example, antiphospholipid syndrome (APS), by detecting antiphospholipid antibodies (aPL) in a sample using a novel target, the lysobisphosphatidic acid (LBPA) bound to the endothelial protein C receptor (EPCR) or an LBPA-binding fragment thereof. Furthermore, the present invention relates to methods for identifying an inhibitor of endothelial protein C receptor (EPCR) function in autoimmune disease, preferably without a side effect on EPCR regulatory function in coagulation, and a method for producing a pharmaceutical composition comprising the steps of identifying a potential inhibitor, and suitably formulating said potential inhibitor into a pharmaceutical composition. Moreover, the present invention relates to said inhibitor as identified or said pharmaceutical composition for use in the prevention and/or treatment of an autoimmune disease, such as, for example, an antiphospholipid syndrome, in a subject. Furthermore, the present invention relates to a method for treating and/or preventing an autoimmune disease, such as, for example, antiphospholipid syndrome, in a subject.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

The present invention relates to prooxidative chain-transfer agents for use in the treatment of a malignant tumour disease, or infectious disease. The prooxidative chain-transfer agents are selected from lipophilic thiols, lipophilic trithiocarbonates, lipophilic, aromatic dithioesters, and lipophilic, aromatic thiols. The compounds amplify the prooxidative activity at the target site and are therefore highly efficient and specific for their targets.

Classes IPC  ?

• A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p. ex. thiols
• A61K 31/10 - SulfuresSulfoxydesSulfones
• A61K 31/275 - NitrilesIsonitriles
• A61P 33/00 - Agents antiparasitaires
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin-1 (TA-MUC1).

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a device and a method for determining the severity of sleep apnoea using electroencephalography and electromyography, wherein the device comprises headgear (10; 110) having a head part (12; 112) covering the head of a patient, at least at the locations where the measuring points C3 and C4 of the electroencephalography are situated, and a chin part (14; 114), and wherein the head part (12; 112) has two electrodes (16; 116) for sensing EEG-signals of the electroencephalography at the electroencephalography points C3 and C4, and the chin part (14, 114) has at least one electrode (18; 118) for sensing the EMG-signal of the electromyography in the chin.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/256 - Électrodes portables, p. ex. avec des sangles ou des bandes
• A61B 5/30 - Circuits d’entrée à cet effet
• A61B 5/372 - Analyse des électroencéphalogrammes
• A61B 5/397 - Analyse des électromyogrammes
• A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
• A61N 2/00 - Magnétothérapie

Abrégé

The present invention relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg)-depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p. ex. contenant des motifs CpG

Abrégé

The present invention relates to modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. The invention further relates to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening. Finally, the invention also relates to methods for the preparation of a modified NK-92 cell that is specific for a target antigen of a target cell in a subject. The invention also relates to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The present invention relates to a compounds consisting of one or more peptides comprising the structure in the following order: A-L1-B-L2-C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, B corresponds to a second amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, C corresponds to a third amino acid sequence that is derived from D or B alpha helical region of human or animal IL-4, or D alpha helical region of human or animal IL-13. L1 and L2 correspond to one or more linking amino acids, wherein said compound is capable of stimulating neuronal axon outgrowth.

Classes IPC  ?

• C07K 14/54 - Interleukines [IL]
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The invention relates to a finger motion rail (2), and a therapeutic device (1) for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a patient. The rail is characterised in that a means (21) arranged laterally next to the respective finger and/or thumb, for bending a finger base joint (31), is designed as a multiple-joint hinge, which, alongside the connection via a first connection lever (2113), via at least one second (and/or third) connection lever (2203; 2204) and at least one connection joint (2114; 2115), is operatively connected to a mechanism (22) also arranged laterally next to the respective finger and/or thumb, for bending a middle knuckle joint (32) and/or a top knuckle joint (33). The finger motion rail (2) according to the invention or a therapeutic device (1) comprising same is notably more resilient towards the effect of pressing, pulling and torsional forces, in particular in relation to a longitudinal axis (LA) of the finger motion rail (2) and it advantageously allows for a more precise and interference-free execution of an anatomically natural, automated finger movement, which increases the chance of successful therapy and the service life of the device.

Classes IPC  ?

• A61H 1/02 - Appareils d'exercice extenseurs ou de ployage

Abrégé

The invention relates to a length-adjustment device (3) for a finger motion rail (2) of a therapeutic device (1) for carrying out a continuous, passive and/or actively assisted movement of a finger and/or a thumb of a hand, a finger motion rail (2) comprising a length-adjustment device (3) of this type, and a corresponding therapeutic device (1) comprising at least one finger motion rail (2) of this type. The invention also relates to a method for adjusting the length of a finger motion rail (2) on a therapeutic device (1) of this type. The length-adjustment device (3) according to the invention or the length-adjustment method according to the invention advantageously allows for a finger motion rail (2) to be automatically shifted along the adjustment rail (30) using the drive (10) already provided on a therapeutic device (1) for the finger motion rail (2), and for same to be fixed on the adjustment rail (30) and therefore on the therapeutic device (1) in a desired position according to the finger length or hand size/length of the user, in order to then be able to carry out a continuous, passive and/or actively assisted movement of a finger and/or of a thumb of a hand in a stable position. Time-consuming manual adjustment is thereby advantageously avoided.

Classes IPC  ?

• A61H 1/02 - Appareils d'exercice extenseurs ou de ployage

Abrégé

The invention relates to a method for classifying a polysomnography recording into defined sleep stages, the method comprising essentially the following steps: dividing the sleep of a person into different identifiable sleep stages; capturing a plurality of pieces of information regarding bodily functions over a specified time period in the form of data, the data comprising at least one data set of a data type of a first nature, by means of which data set the sleep stages can be identified; splitting the captured data into time-dependent data blocks; manually selecting a limited number of training data blocks from the data blocks and associating them with a sleep stage; evaluating the data set of the first nature of each training data block by means of a data-processing method; creating training objects, each training object comprising the evaluated data sets of the first nature of a training data block and the association of the training data block with a sleep stage; transmitting the training objects to a support vector machine for creating a classification; transmitting at least some of the data blocks that were not selected as training data blocks to the support vector machine.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/048 - Détection de la répartition de fréquence dans les signaux
• A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
• A61B 5/0245 - Mesure du pouls ou des pulsations cardiaques utilisant des capteurs engendrant des signaux électriques
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

A catheter for insertion into a vessel (6) is designed at its free end (2) such that, in a first state, it is cylindrical and, in a second state, it has a conical shape, the largest diameter being associated with the peripheral end (2). The aim of the invention is that of providing a catheter of the type mentioned at the outset which avoids thrombus material trapped in a stent from being removed when a stent is retracted.

Classes IPC  ?

• A61F 2/95 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes
• A61B 18/02 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par refroidissement, p. ex. techniques cryogéniques

Abrégé

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to pharmaceutical compositions, comprising at least one oxidative stressor selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The invention further relates pharmaceutical combination preparations comprising these components and the use of such pharmaceutical compositions or combination preparations for use in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations of the invention are in particular useful for topical application on the skin of a human or animal body.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants

Abrégé

3)22333233223. 3. The invention further relates to pharmaceutical compositions comprising one or more of said flavagline derivatives and the use in methods for inhibition of KRAS activation.

Classes IPC  ?

• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a skinfold chamber system comprising a U-shaped folding frame having an outer U-shaped frame part and an inner U-shaped frame part. The two frame parts are coupled to one another at the open ends of the U legs thereof by means of an articulated connection in such a way that the inner frame part can be folded against the outer frame part such that, in the folded-in state, the inner frame part can be or is positioned within the U opening of the outer frame part and, in the folded-out state, the inner frame part and the outer frame part lie mirror-symmetrical to one another and surround an opening. The outer frame part and the inner frame part each have an L-shaped profile in cross-section, and therefore each frame part has a frame wall which is horizontal with respect to the plane of the folding frame and extends in a U shape and a frame wall which is vertical with respect to the plane of the folding frame and extends in a U shape. The two frame parts are oriented relative to one another in such a way that, in the closed position of the folding frame, the vertical frame walls of the two frame parts run approximately parallel to one another and the horizontal frame walls of the two frame parts are oriented substantially in the same plane and in opposite directions with respect to one another.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present invention relates to a pharmaceutical combination, comprising the components: a) at least one regulatory T cell (Treg)-depleting agent, b) at least one Toll-like receptor 9 (TLR9) agonist, c) one or more immune checkpoint inhibitors, for use in the treatment of cancer in humans or non-human mammals.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p. ex. contenant des motifs CpG
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a compound comprising - a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), - a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin- (TA-MUC1).

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to a compound consisting of one or more peptides comprising the structure in the following order: A - L1 - B - L2 - C wherein A corresponds to a first amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, B corresponds to a second amino acid sequence that is derived from A or C alpha helical region of human or animal IL-4 or IL-13, C corresponds to a third amino acid sequence that is derived from D or B alpha helical region of human or animal IL-4, or D alpha helical region of human or animal IL-13. L1 and L2 correspond to one or more linking amino acids, wherein said compound is capable of stimulating neuronal axon outgrowth.

Classes IPC  ?

• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C07K 14/54 - Interleukines [IL]

Abrégé

The present invention relates to vaccines comprising a polypeptide or protein selected from the group consisting of Leishmania major p54, Q4Q8Z6, Q4Q6L9, Q4QHT2, E9AE98, or an immunologically effective fragment thereof, for use in the prevention or treatment of leishmaniasis. The invention further relates to a pharmaceutical composition comprising such a vaccine.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• A61K 39/008 - Antigènes de Leishmania
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

A catheter for insertion into a vessel (6) has a free end (2) designed such that in a first state the catheter is cylindrical and in a second state it is conical, the peripheral end (2) having the largest diameter. The aim of the invention is to devise a catheter of the above-mentioned type which avoids thrombic material that is trapped in a stent from being inadvertently removed when the stent is retracted.

Classes IPC  ?

• A61M 25/00 - CathétersSondes creuses
• A61F 2/95 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes
• A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins

Abrégé

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
• A61K 31/433 - Thiadiazoles
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1α) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-1α or an upstream regulator of Treg-resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/02 - Composés inorganiques
• G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum

Abrégé

The present invention relates to a device for ultrasonic-accelerated hematoma lysis or thrombolysis of intracerebral or intraventricular hemorrhages or hematomas, comprising a body (20) which accommodates a number of separated compartments or lumens consisting of a flushing catheter (1) for flushing fluid and/or pharmaceutically active substances into the intracerebral or intraventricular hemorrhages or hematomas, a drainage catheter (2) for draining fluid from the intracerebral or intraventricular hemorrhages or hematomas, an ultrasonic probe duct (3), and a pressure sensor duct (5), wherein the compartments or lumens are arranged in proximity to each other and wherein in longitudinal extension at least upper-part sections of the compartments or lumens are isolated by walls, wherein the lumen of the pressure sensor duct (5) integrates a pressure sensor (6), and wherein in the lumen of ultrasonic probe duct (3) an endosonographic probe (4) or a stiletto (13) is interchangeably guided.

Classes IPC  ?

• A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
• A61N 7/00 - Thérapie par ultrasons
• A61N 7/02 - Hyperthermie localisée par ultrasons
• A61M 25/00 - CathétersSondes creuses
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

A monitoring assembly comprises probes (1, 4) for inserting into a body, the first probe (1) being coupled to at least one light source (8) or acoustic source in order to generate a stimulation signal and the second probe (4) being arranged in order to detect a response signal of a target organ. The stimulation signal is suitable for differentiating between neuronal tissue and non-neuronal tissue, whereas the response signal is detected as an EMG signal or pressure signal. The two probes are connected to a monitoring computer (15) via control- (9, 13) and evaluation devices (10, 14).

Classes IPC  ?

• A61B 5/04 - Mesure de signaux bioélectriques du corps ou de parties de celui-ci
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61N 7/00 - Thérapie par ultrasons

Abrégé

The present invention relates to a method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), referred to as Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1- alpha, PPARGC1A (PGC-1 a) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. Furthermore, the invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1 A (PGC-lalpha) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PCG-lalpha or an upstream regulator of Treg- resistant T-cells HNF4A, Hdac, RORA, ESRRA, LPIN1 can be used in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention relates to a polymer solution for use as a rheological blood substitute. The rheological blood replacement solution comprises in its basic composition a water-soluble cellulose polymer with a molecular weight of 100 kDa or greater, polyethylene oxide and a solvent. The rheological blood replacement solution of the invention can be used in a variety of applications, e.g. as blood substitute, calibration agent or reference agent. The blood replacement solution is based on a polymer solution, which can also be used as pharmaceutical composition, e.g. for the prevention or treatment of haemorrhage or shock-related disorders.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/38 - CelluloseSes dérivés

Abrégé

The present invention relates to a novel tracheal cannula (10), which allows patients to speak who receive artificial respiration with compressed-air. The tracheal cannula according to the invention makes this possible without the risk that saliva or stomach content is aspirated and without the occurrence of a loss of pressure during the respiration. This is achieved by an embodiment of the cannula having a separated speaking conduit (12) and respiration conduit (11). Furthermore, the invention relates to a speaking respiration system that can be connected to the tracheal cannula of the present invention, and that when used in a patient monitors and controls the respiration of the patient, and simulates an artificial exhalation that enables the tracheostomized patient to speak.

Classes IPC  ?

• A61M 16/04 - Tubes trachéaux
• A61M 16/16 - Dispositifs pour humidifier l'air à respirer
• A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux

Abrégé

The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to methods of identifying the risk of a subject developing lupus nephritis (LN) by measuring the CSF-1 level in a sample obtained from the subject. For a subject having systemic lupus erythematosus (SLE) or in remission of LN, tracking the CSF-1 levels of the subject over time can permit one to predict the likelihood of the subject developing LN or LN flares. For a subject having LN and receiving treatment for LN, the treatment progress can be monitored by tracking the CSF-1 levels of the subject over time. Furthermore, CSF-1 can be a therapeutic target for treating LN.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61P 35/00 - Agents anticancéreux
• A61K 35/26 - LympheGanglions lymphatiquesThymusRateSplénocytesThymocytes

Abrégé

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 9/50 - Microcapsules
• A61K 31/663 - Composés ayant plusieurs groupes acide du phosphore ou leurs esters, p. ex. acide clodronique, acide pamidronique

Abrégé

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G06F 19/18 - pour la génomique ou la protéomique fonctionnelle, p.ex. associations génotype-phénotype, déséquilibre de liaison, mutagénèse, génotypage ou annotation génomique, interactions protéines-protéines ou interactions protéines-acides nucléiques

Abrégé

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and. thus, in the context of personalized cancer vaccines.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G06F 19/18 - pour la génomique ou la protéomique fonctionnelle, p.ex. associations génotype-phénotype, déséquilibre de liaison, mutagénèse, génotypage ou annotation génomique, interactions protéines-protéines ou interactions protéines-acides nucléiques

Abrégé

The present invention relates to a novel tracheal cannula (10), which allows patients to speak who receive artificial respiration with compressed-air. The tracheal cannula according to the invention makes this possible without the risk that saliva or stomach content is aspirated and without the occurrence of a loss of pressure during the respiration. This is achieved by an embodiment of the cannula having a separated speaking conduit (12) and respiration conduit (11). Furthermore, the invention relates to a speaking respiration system that can be connected to the tracheal cannula of the present invention, and that when used in a patient monitors and controls the respiration of the patient, and simulates an artificial exhalation that enables the tracheostomized patient to speak.

Classes IPC  ?

• A61M 16/04 - Tubes trachéaux

Abrégé

The present invention relates to a method for the early diagnosis of a clinically latent placental insufficiency in pathological placental maturation, and the prophylaxis of an intrauterine fetal hypoxia/asphyxia at the due date or after a prolonged gestation, comprising determining the amount and/or the concentration of the biomarker prokineticin 1 (EG-VEGF) and/or its receptor PKR1 and/or PKR2 in a sample from the pregnant subject and/or the pregnancy. In a preferred embodiment, the invention is based on determining the ratio of the amount and/or the concentration of bFGF/PK1 as a measure of current functional condition and an indicator of latent clinical problems such as placental dysfunction resulting in fetal hypoxia.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
• A61K 38/28 - Insulines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to novel tumor-associated antigens,which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells,which are specifically reactive to the antigens of the invention in an MHC-independent manner.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.

Classes IPC  ?

• C12N 15/67 - Méthodes générales pour favoriser l'expression
• C12N 15/68 - Stabilisation du vecteur
• C12N 15/69 - Augmentation du nombre de copies du vecteur

Abrégé

The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.

Classes IPC  ?

• C12N 15/67 - Méthodes générales pour favoriser l'expression
• C12N 15/68 - Stabilisation du vecteur
• C12N 15/69 - Augmentation du nombre de copies du vecteur

Abrégé

The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present invention relates to a balloon catheter system for sealing puncture points or openings in body cavities, hollow organs or in percutaneous drainage operations in mammals, consisting of a filling catheter on the distal end of which a first balloon can be filled with the filling medium is arranged with a further balloon arranged proximally spaced apart therefrom. The balloons close the puncture point or the opening on the two sides in the filled state of the balloon. A hollow needle open at the shaft or the shaft end can be guided in the lumen of the filling catheter for filling the two balloons with the filling medium, wherein the shells of the two balloons enclose the shaft of the filling catheter. The filling catheter in each case has an opening arranged in the balloon lumen to fill the two balloons.

Classes IPC  ?

• A61M 29/00 - Dilatateurs avec ou sans moyens pour introduire des agents, p. ex. des remèdes
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique
• A61M 25/10 - Cathéters à ballon
• A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins

Abrégé

The Invention relates to a particulate system for use in diminishing cell growth, in particular the growth of cancer cells, comprising one or more water soluble lanthanide compounds that are embedded in a solid biodegradable polymer particle, the polymer being selected from the group consisting of polycarbonic acids, polylactic acids, polyglycolic acids, polypeptides or combinations thereof.

Classes IPC  ?

• A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61P 35/00 - Agents anticancéreux
• A61P 31/10 - Antifongiques
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention provides novel photoactivatable paclitaxel derivatives wherein the C2 and C7 positions of the paclitaxel molecule are substituted with a photocleavable moiety such as a chromophore. Typically, the chromophore is selected from the group comprising 2-nitrobenzyl ethers, carbamates or carbonates and their 4,5-dialkoxy substituted variants; 2-nitrophenylethyl ethers, carbamates or carbonates and their 4,5-dialkoxy substituted variants, or their p-substituted derivatives; oc-carboxy-2-nitrobenzyl ethers, carbamates or carbonates and their 4,5-dialkoxy substituted variants; 2(2-nitro- phenyl) ethyl ethers, carbamates or carbonates and their 4,5-dialkoxy substituted variants; coumarin-4-ylmethyl ethers, or carbonates and their 7-alkoxy, 6, 7-dialkoxy, 6-bromo-7-alkoxy or 7-dialkylamino substituted variants; p-hydroxyphenacyl ethers or carbamates and their meta-substituted derivatives or structurally related compounds. More specifically, the chromophore is 4, 5-dimethoxy-2- nitrobenyloxycarbonyl (Nvoc) or a structurally related compound. Further aspects of the invention relate to the use of these paclitaxel derivatives in biological, medical and pharmaceutical applications, in particular in cellbiology and cancer treatment. A closely related aspect is an antitumor medicament comprising the above paclitaxel derivatives.

Classes IPC  ?

• C07D 305/14 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for the early diagnosis of a clinically latent placental insufficiency in pathological placental maturation, and the prophylaxis of an intrauterine fetal hypoxia/asphyxia at the due date or after a prolonged gestation, comprising determining the amount and/or the concentration of the biomarker prokineticin 1 (EG-VEGF) and/or its receptor PKR1 and/or PKR2 in a sample from the pregnant subject and/or the pregnancy. In a preferred embodiment, the invention is based on determining the ratio of the amount and/or the concentration of b FGF/PK1 as a measure of current functional condition and an indicator of latent clinical problems such as placental dysfunction resulting in fetal hypoxia.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC. The invention further encompasses pharmaceutical compositions containing the scARC of the invention and the use of the scARC in therapy of cancerous or infectious diseases, or for use in the quantification and/or visualization of disease associated antigens.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Abrégé

The present invention relates to enhancing RNA expression in a cell such as a cell transfected with RNA by reducing the activity of RNA-dependent protein kinase (PKR). Thus, the present invention provides methods for expressing RNA in a cell comprising the step of reducing the activity of RNA-dependent protein kinase (PKR) in the cell. Reducing the activity of RNA-dependent protein kinase (PKR) in the cell increases the stability of RNA and/or increases the expression of RNA in the cell.

Classes IPC  ?

• C12N 15/67 - Méthodes générales pour favoriser l'expression
• C12N 5/16 - Cellules animales